 |
34 Diseases |  |
9 Trials |
|
9 Trials |  |
673 News |  |
| «12345678» |
- | emtricitabine/tenofovir disoproxil fumarate / Generic mfg.
Enrollment closed, Trial completion date, Trial primary completion date, Head-to-Head: ADVANCE Study of DTG + TAF + FTC vs DTG + TDF + FTC and EFV + TDF+FTC in First-line Antiretroviral Therapy (clinicaltrials.gov) - Feb 19, 2019
P3, N=1110, Active, not recruiting, Sponsor: Willem Daniel Francois Venter
Recruiting --> Active, not recruiting | Trial completion date: Dec 2018 --> Apr 2020 | Trial primary completion date: Dec 2017 --> Apr 2019
- | efavirenz / Generic mfg.
Enrollment closed: VESTED: Evaluating the Efficacy and Safety of Dolutegravir-Containing Versus Efavirenz-Containing Antiretroviral Therapy Regimens in HIV-1-Infected Pregnant Women and Their Infants (clinicaltrials.gov) - Feb 18, 2019
P3, N=639, Active, not recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting --> Active, not recruiting | Trial completion date: Dec 2018 --> Apr 2020 | Trial primary completion date: Dec 2017 --> Apr 2019 Recruiting --> Active, not recruiting
- || tenofovir disoproxil fumarate / Generic mfg., efavirenz / Generic mfg., efavirenz/emtricitabine/tenofovir disoproxil fumarate / Generic mfg.
Enrollment closed, Trial completion date, Trial primary completion date: Therapeutic Drug Monitoring Study of Reduced-Dose Efavirenz (400 mg) in Combo Tablet for Patients Receiving Atripla With Viral Suppression in Taiwan (clinicaltrials.gov) - Feb 15, 2019
P3, N=50, Active, not recruiting, Sponsor: Yu-Jay Corp.
Recruiting --> Active, not recruiting Not yet recruiting --> Active, not recruiting | Trial completion date: Apr 2019 --> Dec 2019 | Trial primary completion date: Mar 2019 --> Jul 2019
- | efavirenz / Generic mfg.
Trial completion date, Trial primary completion date: VESTED: Evaluating the Efficacy and Safety of Dolutegravir-Containing Versus Efavirenz-Containing Antiretroviral Therapy Regimens in HIV-1-Infected Pregnant Women and Their Infants (clinicaltrials.gov) - Dec 17, 2018
P3, N=639, Recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Not yet recruiting --> Active, not recruiting | Trial completion date: Apr 2019 --> Dec 2019 | Trial primary completion date: Mar 2019 --> Jul 2019 Trial completion date: Nov 2020 --> Jul 2020 | Trial primary completion date: Nov 2020 --> Jul 2020
- |||| Prezcobix (darunavir/cobicistat) / Gilead, J&J, Tivicay (dolutegravir) / ViiV Healthcare
New P4 trial: EFFICACY AND SAFETY OF A SIMPLIFICATION TREATMENT BASED ON DOLUTEGRAVIR AND DARUNAVIR / COBICISTAT VS USUAL TREATMENT IN SUPPRESSED HIV-1-INFECTED PATIENTS WITH MULTIDRUG RESISTANCE. Eficacia y seguridad de Dolutegravir m (EUDRACT) - Dec 4, 2018
P4, N=100, Ongoing, Sponsor: FUNDACI
- | Trial completion date, Metastases: Three Chemo Regimens as an Adjunct to ART for Treatment of Advanced AIDS-KS (clinicaltrials.gov) - Oct 17, 2018
P3, N=334, Active, not recruiting, Sponsor: AIDS Clinical Trials Group
Trial completion date: Nov 2020 --> Jul 2020 | Trial primary completion date: Nov 2020 --> Jul 2020 Trial completion date: Dec 2022 --> Mar 2020
- | Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
Enrollment open, Trial initiation date: B/F/TAF vs Atripla Double-Blind Switch Study in HIV-1 Infected Adults (clinicaltrials.gov) - Oct 1, 2018
P4, N=200, Recruiting, Sponsor: University of Alberta
Trial completion date: Dec 2022 --> Mar 2020 Not yet recruiting --> Recruiting | Initiation date: Jul 2018 --> Oct 2018
- | Enrollment closed, Trial completion date, Metastases: Three Chemo Regimens as an Adjunct to ART for Treatment of Advanced AIDS-KS (clinicaltrials.gov) - Sep 26, 2018
P3, N=334, Active, not recruiting, Sponsor: AIDS Clinical Trials Group
Not yet recruiting --> Recruiting | Initiation date: Jul 2018 --> Oct 2018 Completed --> Active, not recruiting | Trial completion date: Mar 2018 --> Dec 2022
- | Tybost (cobicistat) / Gilead, Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) / Gilead, Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate) / Gilead, Japan Tobacco
Trial completion date: Study to Evaluate Switching From a TDF-Containing Combination Regimen to a TAF-Containing Fixed Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Positive Participants (clinicaltrials.gov) - Aug 31, 2018
P3, N=1443, Active, not recruiting, Sponsor: Gilead Sciences
Completed --> Active, not recruiting | Trial completion date: Mar 2018 --> Dec 2022 Trial completion date: Jun 2018 --> Jan 2019
- | tenofovir disoproxil fumarate / Generic mfg., efavirenz / Generic mfg., efavirenz/emtricitabine/tenofovir disoproxil fumarate / Generic mfg.
New P3 trial: Therapeutic Drug Monitoring Study of Reduced-Dose Efavirenz (400 mg) in Combo Tablet for Patients Receiving Atripla With Viral Suppression in Taiwan (clinicaltrials.gov) - Jul 22, 2018
P3, N=50, Not yet recruiting, Sponsor: Yu-Jay Corp.
- | Trial completion, Enrollment change, Trial completion date, Trial primary completion date, Metastases: Three Chemo Regimens as an Adjunct to ART for Treatment of Advanced AIDS-KS (clinicaltrials.gov) - Jun 7, 2018
P3, N=334, Completed, Sponsor: AIDS Clinical Trials Group
Trial completion date: Jun 2018 --> Jan 2019 Recruiting --> Completed | N=706 --> 334 | Trial completion date: Dec 2022 --> Mar 2018 | Trial primary completion date: Dec 2019 --> Mar 2018
- ||| Delstrigo (doravirine/lamivudine/tenofovir disoproxil fumarate) / Merck (MSD)
Trial completion date: DRIVE-AHEAD: Comparison of Doravirine, Tenofovir, Lamivudine (MK-1439A) and ATRIPLA (clinicaltrials.gov) - Jun 3, 2018
P3, N=734, Active, not recruiting, Sponsor: Merck Sharp & Dohme Corp.
Recruiting --> Completed | N=706 --> 334 | Trial completion date: Dec 2022 --> Mar 2018 | Trial primary completion date: Dec 2019 --> Mar 2018 Trial completion date: Feb 2020 --> Nov 2021
- ||| Complera (emtricitabine/rilpivirine/tenofovir) / Gilead, J&J, Odefsey (emtricitabine/rilpivirine/tenofovir alafenamide) / J&J, Gilead
Trial completion date: Study to Evaluate Switching From a Regimen Consisting of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (EFV/FTC/TDF) Fixed Dose Combination (FDC) to Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) FDC in Virologically-Suppressed, HIV-1 Infected Adults (clinicaltrials.gov) - Jun 3, 2018
P3b, N=881, Active, not recruiting, Sponsor: Gilead Sciences
Trial completion date: Feb 2020 --> Nov 2021 Trial completion date: May 2018 --> Dec 2018
- |||| Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
New P4 trial: B/F/TAF vs Atripla Double-Blind Switch Study in HIV-1 Infected Adults (clinicaltrials.gov) - May 27, 2018
P4, N=200, Not yet recruiting, Sponsor: University of Alberta
- | efavirenz / Generic mfg.
Trial completion date, Trial primary completion date: Pharmacologic Strategies to Use the Levonorgestrel Implant in HIV-infected Women (clinicaltrials.gov) - Apr 24, 2018
P2, N=28, Active, not recruiting, Sponsor: University of Nebraska
Trial completion date: May 2018 --> Dec 2018 Trial completion date: Jul 2018 --> Dec 2019 | Trial primary completion date: Dec 2017 --> Dec 2019
- || Delstrigo (doravirine/lamivudine/tenofovir disoproxil fumarate) / Merck (MSD)
Trial completion date, Trial primary completion date: Effects of Switching From ATRIPLA (clinicaltrials.gov) - Mar 6, 2018
P2b, N=84, Active, not recruiting, Sponsor: Merck Sharp & Dohme Corp.
Trial completion date: Jul 2018 --> Dec 2019 | Trial primary completion date: Dec 2017 --> Dec 2019 Trial completion date: Sep 2018 --> Jul 2020 | Trial primary completion date: Feb 2018 --> Sep 2018
- | Edurant (rilpivirine) / J&J, Complera (emtricitabine/rilpivirine/tenofovir) / Gilead, J&J
Trial primary completion date: STEREOS: Switching TDF/FTC/EFV to TDF/FTC/RPV VS Continuing TDF/FTC/EFV in HIV Patients With Complete Virological Suppression (clinicaltrials.gov) - Jan 24, 2018
P=N/A, N=244, Active, not recruiting, Sponsor: Mahidol University
Trial completion date: Sep 2018 --> Jul 2020 | Trial primary completion date: Feb 2018 --> Sep 2018 Trial primary completion date: Dec 2017 --> Mar 2018
- | Clinical, Journal: Allogeneic stem cell transplantation for HIV-positive patients with hematologic malignancies: report of 5 cases after 2010. (Pubmed Central) - Dec 25, 2017
One patient had acute renal failure that resolved after discontinuation of TDF. Our findings support considering selected HIV-infected patients for allo-HSCT when indicated for the management of their hematologic malignancies.
- | efavirenz/emtricitabine/tenofovir disoproxil fumarate / Generic mfg.
Clinical, Journal: Vitamin D Supplementation Does Not Affect Metabolic Changes Seen With ART Initiation. (Pubmed Central) - Dec 20, 2017
Vit D/Cal supplementation over 48 weeks did not alter the lipid profile or glucose metabolism experienced with initiation of EFV/FTC/TDF in ART-naïve persons. Vitamin D supplementation is unlikely to be an effective strategy to attenuate metabolic dysregulations with ART initiation.
- | efavirenz / Generic mfg.
Enrollment open, Trial primary completion date: VESTED: Evaluating the Efficacy and Safety of Dolutegravir-Containing Versus Efavirenz-Containing Antiretroviral Therapy Regimens in HIV-1-Infected Pregnant Women and Their Infants (clinicaltrials.gov) - Dec 18, 2017
P3, N=549, Recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Vitamin D supplementation is unlikely to be an effective strategy to attenuate metabolic dysregulations with ART initiation. Not yet recruiting --> Recruiting | Trial primary completion date: May 2020 --> Nov 2020 | Not yet recruiting --> Recruiting | Trial primary completion date: May 2020 --> Nov 2020 | Not yet recruiting --> Recruiting | Trial primary completion date: May 2020 --> Nov 2020
- ||| Delstrigo (doravirine/lamivudine/tenofovir disoproxil fumarate) / Merck (MSD)
Enrollment closed: Effects of Switching From ATRIPLA (clinicaltrials.gov) - Nov 17, 2017
P2b, N=84, Active, not recruiting, Sponsor: Merck Sharp & Dohme Corp.
Not yet recruiting --> Recruiting | Trial primary completion date: May 2020 --> Nov 2020 | Not yet recruiting --> Recruiting | Trial primary completion date: May 2020 --> Nov 2020 | Not yet recruiting --> Recruiting | Trial primary completion date: May 2020 --> Nov 2020 Recruiting --> Active, not recruiting
- |||| Complera (emtricitabine/rilpivirine/tenofovir) / Gilead, J&J
Trial completion, Trial primary completion date: ESCAPE: Effect of SwitChing AtriPla to Eviplera on Neurocognitive and Emotional Functioning (clinicaltrials.gov) - Oct 27, 2017
P4, N=58, Completed, Sponsor: UMC Utrecht
Recruiting --> Active, not recruiting Recruiting --> Completed | Trial primary completion date: Nov 2016 --> Jun 2017
- | efavirenz/emtricitabine/tenofovir disoproxil fumarate / Generic mfg.
New P4 trial: Bioequivalence Study of Two Formulatiosns With the Asscociaton of Efavirenz, Emtricitabine and Tenofovir (clinicaltrials.gov) - Oct 13, 2017
P4, N=24, Completed, Sponsor: Laboratorio Elea S.A.C.I.F. y A.
- | Edurant (rilpivirine) / J&J, Complera (emtricitabine/rilpivirine/tenofovir) / Gilead, J&J
Trial completion: SSAT058: Atripla to Eviplera Switch in Patients Without Central Nervous System Symptoms (clinicaltrials.gov) - Sep 18, 2017
P4, N=40, Completed, Sponsor: St Stephens Aids Trust
Recruiting --> Completed | Trial primary completion date: Nov 2016 --> Jun 2017 Active, not recruiting --> Completed
- | Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate) / Gilead, Japan Tobacco
Trial primary completion date: SABES: HIV Test and Treat to Prevent HIV Transmission Among MSM and Transgender Women (clinicaltrials.gov) - Sep 1, 2017
P4, N=150, Recruiting, Sponsor: Fred Hutchinson Cancer Research Center
Active, not recruiting --> Completed Trial primary completion date: Jun 2017 --> Jun 2020
- | Descovy (emtricitabine/tenofovir alafenamide) / Gilead
Clinical: VESTED: Evaluating the Efficacy and Safety of Dolutegravir-Containing Versus Efavirenz-Containing Antiretroviral Therapy Regimens in HIV-1-Infected Pregnant Women and Their Infants (clinicaltrials.gov) - Aug 21, 2017
P3, N=549, Not yet recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Trial primary completion date: Jun 2017 --> Jun 2020 Initiation date: Jul 2017 --> Nov 2017
- | Edurant (rilpivirine) / J&J, Complera (emtricitabine/rilpivirine/tenofovir) / Gilead, J&J
New trial: STEREOS: Switching TDF/FTC/EFV to TDF/FTC/RPV VS Continuing TDF/FTC/EFV in HIV Patients With Complete Virological Suppression (clinicaltrials.gov) - Aug 15, 2017
P=N/A, N=244, Active, not recruiting, Sponsor: Mahidol University
- | Enrollment closed, Trial primary completion date: STATIS: Systematic Empirical vs. Test-guided Anti-TB Treatment Impact in Severely Immunosuppressed HIV-infected Adults Initiating ART With CD4 Cell Counts <100/mm3 (clinicaltrials.gov) - Jul 12, 2017
P4, N=1050, Active, not recruiting, Sponsor: French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)
Initiation date: Jul 2017 --> Nov 2017 Recruiting --> Active, not recruiting | Trial primary completion date: Apr 2017 --> Nov 2017
- | efavirenz / Generic mfg.
Enrollment closed: Pharmacologic Strategies to Use the Levonorgestrel Implant in HIV-infected Women (clinicaltrials.gov) - Jun 22, 2017
P2, N=28, Active, not recruiting, Sponsor: University of Nebraska
Recruiting --> Active, not recruiting | Trial primary completion date: Apr 2017 --> Nov 2017 Recruiting --> Active, not recruiting
- efavirenz / Generic mfg.
Trial primary completion date: Pharmacokinetics of Efavirenz in the Presence of Rifampicin and Isoniazid (clinicaltrials.gov) - Jun 21, 2017
P1, N=35, Recruiting, Sponsor: St Stephens Aids Trust
Recruiting --> Active, not recruiting Trial primary completion date: Jun 2017 --> Jan 2018
- | Complera (emtricitabine/rilpivirine/tenofovir) / Gilead, J&J
Trial completion: Evolution of Plasma Lipid Profile in Patients With HIV1 Who Change Atripla to Eviplera Compared to Continue With Atripla (clinicaltrials.gov) - Jun 14, 2017
P4, N=30, Completed, Sponsor: Hospital Universitari Vall d'Hebron Research Institute
Trial primary completion date: Jun 2017 --> Jan 2018 Active, not recruiting --> Completed
- | efavirenz / Generic mfg.
Phase classification: LAAM-HAART PET Imaging (clinicaltrials.gov) - Jun 9, 2017
P, N=10, Completed, Sponsor: Washington University School of Medicine
Active, not recruiting --> Completed Phase classification: P=N/A --> P
- | Complera (emtricitabine/rilpivirine/tenofovir) / Gilead, J&J
Enrollment change, Trial termination, Adverse events: DeepSwitch: Decrease of Neuropsychiatric Side Effects After Switching From Atripla to Eviplera (clinicaltrials.gov) - Apr 27, 2017
P4, N=25, Terminated, Sponsor: Sheba Medical Center
Phase classification: P=N/A --> P N=40 --> 25 | Recruiting --> Terminated; no more participants taking atripla
- | emtricitabine/tenofovir disoproxil fumarate / Generic mfg.
New P3 trial, Head-to-Head: ADVANCE Study of DTG + TAF + FTC vs DTG + TDF + FTC and EFV + TDF+FTC in First-line Antiretroviral Therapy (clinicaltrials.gov) - Apr 20, 2017
P3, N=1110, Recruiting, Sponsor: Willem Daniel Francois Venter
- | efavirenz / Generic mfg.
Enrollment open, Trial initiation date, Trial primary completion date: Pharmacologic Strategies to Use the Levonorgestrel Implant in HIV-infected Women (clinicaltrials.gov) - Apr 19, 2017
P2, N=28, Recruiting, Sponsor: University of Nebraska
N=40 --> 25 | Recruiting --> Terminated; no more participants taking atripla Not yet recruiting --> Recruiting | Initiation date: Nov 2016 --> Apr 2017 | Trial primary completion date: Jun 2017 --> Jan 2018
- || Edurant (rilpivirine) / J&J, Complera (emtricitabine/rilpivirine/tenofovir) / Gilead, J&J
Phase classification, Head-to-Head: SALIF: A Clinical Trial Comparing the Efficacy of Tenofovir Disoproxil Fumarate/Emtricitabine/Rilpivirine (TDF/FTC/RPV) Versus TDF/FTC/Efavirenz (TDF/FTC/EFV) in Patients With Undetectable Plasma HIV-1 RNA on Current First-line Treatment (clinicaltrials.gov) - Apr 11, 2017
P3b, N=426, Active, not recruiting, Sponsor: Janssen-Cilag International NV
Not yet recruiting --> Recruiting | Initiation date: Nov 2016 --> Apr 2017 | Trial primary completion date: Jun 2017 --> Jan 2018 Phase classification: P3 --> P3b
- Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate) / Gilead, Japan Tobacco
Trial primary completion date: SABES: HIV Test and Treat to Prevent HIV Transmission Among MSM and Transgender Women (clinicaltrials.gov) - Feb 11, 2017
P4, N=150, Recruiting, Sponsor: Fred Hutchinson Cancer Research Center
Phase classification: P3 --> P3b Trial primary completion date: Dec 2016 --> Jun 2017
- || Descovy (emtricitabine/tenofovir alafenamide) / Gilead
Clinical: VESTED: Evaluating the Efficacy and Safety of Dolutegravir-Containing Versus Efavirenz-Containing Antiretroviral Therapy Regimens in HIV-1-Infected Pregnant Women and Their Infants (clinicaltrials.gov) - Feb 9, 2017
P3, N=549, Not yet recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
- efavirenz / Generic mfg.
Enrollment open: Pharmacokinetics of Efavirenz in the Presence of Rifampicin and Isoniazid (clinicaltrials.gov) - Dec 28, 2016
P1, N=35, Recruiting, Sponsor: St Stephens Aids Trust
Trial primary completion date: Dec 2016 --> Jun 2017 Not yet recruiting --> Recruiting
- | Edurant (rilpivirine) / J&J, Complera (emtricitabine/rilpivirine/tenofovir) / Gilead, J&J
Enrollment closed: SSAT058: Atripla to Eviplera Switch in Patients Without Central Nervous System Symptoms (clinicaltrials.gov) - Nov 29, 2016
P4, N=40, Active, not recruiting, Sponsor: St Stephens Aids Trust
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- || Delstrigo (doravirine/lamivudine/tenofovir disoproxil fumarate) / Merck (MSD)
Trial primary completion date: Effects of Switching From ATRIPLA (clinicaltrials.gov) - Nov 17, 2016
P2b, N=84, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
Recruiting --> Active, not recruiting Trial primary completion date: Feb 2017 --> Nov 2017
- efavirenz / Generic mfg.
Trial initiation date: Pharmacologic Strategies to Use the Levonorgestrel Implant in HIV-infected Women (clinicaltrials.gov) - Oct 26, 2016
P2, N=28, Not yet recruiting, Sponsor: University of Nebraska
Trial primary completion date: Feb 2017 --> Nov 2017 Initiation date: Jun 2017 --> Nov 2016
- |||| Complera (emtricitabine/rilpivirine/tenofovir) / Gilead, J&J
Enrollment open, Trial primary completion date: ESCAPE: Effect of SwitChing AtriPla to Eviplera on Neurocognitive and Emotional Functioning (clinicaltrials.gov) - Oct 25, 2016
P4, N=60, Recruiting, Sponsor: UMC Utrecht
Initiation date: Jun 2017 --> Nov 2016 Not yet recruiting --> Recruiting | Trial primary completion date: Jan 2016 --> Nov 2016
- | Adempas (riociguat) / Bayer, Merck (MSD)
Trial completion: Interaction With HIV Antiretroviral Agents (clinicaltrials.gov) - Oct 20, 2016
P1, N=40, Completed, Sponsor: Bayer
Not yet recruiting --> Recruiting | Trial primary completion date: Jan 2016 --> Nov 2016 Recruiting --> Completed
- ||| Delstrigo (doravirine/lamivudine/tenofovir disoproxil fumarate) / Merck (MSD)
Enrollment change: Effects of Switching From ATRIPLA (clinicaltrials.gov) - Oct 17, 2016
P2b, N=84, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
Recruiting --> Completed N=106 --> 84
- Adempas (riociguat) / Bayer, Merck (MSD)
Trial primary completion date: Interaction With HIV Antiretroviral Agents (clinicaltrials.gov) - Oct 12, 2016
P1, N=40, Recruiting, Sponsor: Bayer
N=106 --> 84 Trial primary completion date: Apr 2017 --> Oct 2016
- Trial primary completion date, IO biomarker, Metastases: Three Chemo Regimens as an Adjunct to ART for Treatment of Advanced AIDS-KS (clinicaltrials.gov) - Sep 21, 2016
P3, N=706, Recruiting, Sponsor: AIDS Clinical Trials Group
Trial primary completion date: Apr 2017 --> Oct 2016 Trial primary completion date: Jun 2027 --> Dec 2019
- efavirenz/emtricitabine/tenofovir disoproxil fumarate / Generic mfg.
Trial completion, Enrollment change, Trial primary completion date: Impact of Immediate Versus South African Recommendations Guided ART Initiation on HIV Incidence (clinicaltrials.gov) - Jul 23, 2016
P=N/A, N=28153, Completed, Sponsor: French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)
Trial primary completion date: Jun 2027 --> Dec 2019 Recruiting --> Completed | N=22000 --> 28153 | Trial primary completion date: Mar 2016 --> Jun 2016
- || Delstrigo (doravirine/lamivudine/tenofovir disoproxil fumarate) / Merck (MSD)
Trial primary completion date: Effects of Switching From ATRIPLA (clinicaltrials.gov) - Jul 19, 2016
P2b, N=106, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
Recruiting --> Completed | N=22000 --> 28153 | Trial primary completion date: Mar 2016 --> Jun 2016 Trial primary completion date: Nov 2016 --> Feb 2017
- || Complera (emtricitabine/rilpivirine/tenofovir) / Gilead, J&J, Odefsey (emtricitabine/rilpivirine/tenofovir alafenamide) / J&J, Gilead
Phase classification: Study to Evaluate Switching From a Regimen Consisting of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (EFV/FTC/TDF) Fixed Dose Combination (FDC) to Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) FDC in Virologically-Suppressed, HIV-1 Infected Adults (clinicaltrials.gov) - Jul 18, 2016
P3b, N=877, Active, not recruiting, Sponsor: Gilead Sciences
Trial primary completion date: Nov 2016 --> Feb 2017 Phase classification: P3 --> P3b